A tissue-penetrably engineered deoxyribonuclease 1 to prevent nasal polyp formation in chronic rhinosinusitis Authors: Su-Bin Kwak, Roza Khalmuratova, Sang-Jin Kim, Hyun-Woo Shin, Jong-Wan Park Published: 2025 ABSTRACT BackgroundNeutrophilic chronic rhinosinusitis (CRS) is characterized by persistent inflammation and often responds poorly to corticosteroid therapy. In this disease, neutrophil extracellular traps (NETs) are increasingly recognized as key mediators of mucosal damage and polypogenesis. The removal of NETs by deoxyribonuclease 1 could be a potential therapeutic approach to overcome steroid resistance in neutrophilic CRS. In this study, we established a mouse model of neutrophilic CRS and evaluated the effect of a genetically engineered deoxyribonuclease 1 ‘AR-CR8 Dnase1’ on NETs and polyp formation in the mice.MethodsHuman neutrophils were isolated and treated with LPS to induce NET formation. An animal model for neutrophilic CRS and polyps was developed by intranasal administration of LPS and Staphylococcal toxin. H&E staining and immunofluorescence were performed to identify polyps, NETs, and immune cells in nasal cavities.ResultsAR-CR8 Dnase1 effectively degraded NET-like structures in LPS-stimulated human neutrophils. In the mouse CRS model, the intranasal administration of AR-CR8 Dnase1 noticeably reduced the burden of nasal polyps. The intranasal treatment of Dnase1 was effective as much as an injection of dexamethasone in reducing polyp number and NET accumulation in this model.ConclusionsThese results suggest that an engineered deoxyribonuclease 1 like AR-CR8 Dnase1 be an emerging bio-drug to inhibit inflammatory reaction and polyp formation in patients with neutrophilic CRS. AR-CR8 Dnase1 may be an alternative therapeutic for patients with CRS who are not suitable for steroid therapy, and further studies comparing dosing, durability, and safety are needed before considering clinical use.Trial registrationNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40360-025-01066-z. Background Chronic rhinosinusitis (CRS) is an inflammatory disease in the nasal or paranasal sinus mucosa and persists for more than 12 weeks despite medical treatment [1]. Clinically, it is classified into two subtypes: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP) [2, 3]. In terms of the population of infiltrating immune cells, CRS is also categorized as two subtypes: Eosinophilic (eosinophils enriched) and Neutrophilic (neutrophils enriched) CRS [4]. Compared with eosinophilic type, neutrophilic CRS is more common in Asians and often associated with severe symptoms and tissue remodeling [5, 6]. This disease significantly reduces the patient’s quality of life due to recurrent infections, chronic nasal congestion, and sleep disturbances. Recent studies have shown that neutrophil extracellular traps (NETs) critically contribute to nasal inflammation and polyp formation [7–9]. NETs are composed of DNAs, histones and various antimicrobial proteins. As NETs capture and kill invading pathogens, they are essential for host defense [10]. However, it has been reported that excess NETs could worsen the symptoms of various inflammatory diseases, including CRS [11–13]. Therefore, NETs per se and the cellular process for NET formation are regarded as emerging targets for treating CRS and nasal polyps. Since deoxyribonuclease 1 degrades extracellular DNAs, it has been investigated as a therapeutic agent to eliminate the DNA-based NETs in various inflammatory diseases [14–16]. However, the clinical application of native deoxyribonuclease 1 is limited because this enzyme is short-lived and quickly inactivated in the blood [17–19]. Moreover, the native form of the enzyme cannot be used for nasal administration because this enzyme is too big to penetrate into cells or tissues [20]. Recently, we developed a genetically engineered deoxyribonuclease 1 which is resistant to enzyme inactivation by plasma proteins and also penetrable to biological membranes [21]. In this study, we validated the therapeutic effect of the engineered deoxyribonuclease 1 on polyp formation in a mouse model for neutrophilic CRS. Materials and methods Animals BALB/c mice were purchased from Orient Bio Inc. (Seongnam, Korea). The animals were kept in a special pathogen-free biohazard containment facility. The protocols were approved by the Institutional Animal Care and Use Committee of Seoul National University (SNU-240403-2-3, Approval year: 2024). Animals were maintained in the facility accredited AAALAC International in accordance with Guide for the Care and Use of Laboratory Animals 8th edition (https://www.ncbi.nlm.nih.gov/books/NBK54050/). The study was carried out with four-week-old, male BALB/c mice. Fifty mice were randomly divided into five groups, each of which included ten mice, to evaluate the effects of Dnase1 on neutrophilic chronic rhinosinusitis. Isolation of human neutrophils Fresh human blood samples were collected in EDTA-containing tubes and diluted in phosphate-buffered saline (PBS). To isolate granulocytes, the diluted samples were layered onto a Bicoll-separating solution (Biochrom; Cambridge, UK) and centrifuged at 700 × g for 20 minutes. After density gradient centrifugation, the RBC-granulocyte pellet was harvested, and residual red blood cells (RBCs) were lysed using a buffer composed of 0.1 mM EDTA, 12 mM sodium bicarbonate, and 155 mM ammonium chloride. The lysed samples were centrifuged at 700 × g for 10 minutes, and the remaining cell pellet was resuspended in RPMI medium supplemented with 10% fetal bovine serum (FBS). The isolated cells were then incubated at a density of 1 × 106 cells/mL in the presence of granulocyte colony-stimulating factor (G-CSF) for 16 hours. Experimental procedures to obtain human neutrophils were approved by the Institutional Review Board of Seoul National University Hospital (C-2208-143-1353). Preparation of recombinant Dnase1 Dnase1 was produced with reference to previous study [21]. BL21 E.coli cells were transformed with the pET28 vector harboring the WT Dnase1 or AR-CR8 Dnase1 gene, and cultured overnight at 37 °C in 10 mL of LB broth containing kanamycin. On the next day, the cells were transferred to 200 mL of fresh LB broth and incubated at 37 °C with shaking at 200 rpm for 1 hour until the optical density at 600 nm reached approximately 0.4 - 0.8. Protein expression was induced by adding 1 mM IPTG, followed by incubation at 37 °C for 3 hours. The cells were harvested by centrifugation at 4000 × g for 15 minutes at 4 °C, resuspended in phosphate-buffered saline (PBS, pH 8.0), and disrupted by sonication on ice for 30 minutes. The lysate was then suspended in 1 M urea solution and stored at −20 °C. After thawing the lysate at 4 °C, it was centrifuged at 5600 × g for 10 minutes to remove cellular debris, and the supernatant containing the soluble protein fraction was collected. Nickel-NTA agarose beads (Qiagen; Hilden, Germany) were added to the supernatant and incubated at 4 °C for 1 hour with gentle rotation to allow for His-tagged protein binding. The beads were washed with PBS containing 20 mM imidazole to remove nonspecific proteins, and the target proteins were eluted with 250 mM imidazole. To remove endotoxins, the eluate was processed using the ToxinCleanic Endotoxin Removal Kit (Bioneer; Daejeon, South Korea). Finally, the buffer was exchanged to PBS using Amicon Ultra centrifugal filters (Millipore; Burlington, MA, USA). A mouse model for neutrophilic CRS Neutrophilic nasal polyp (NP) lesions in mice were induced according to a previously established protocol [9]. Mice were immunized intraperitoneally (i.p.) with 25 μg of ovalbumin (OVA; Sigma-Aldrich, St. Louis, MO, USA) and 20 μg of lipopolysaccharide (LPS; Sigma-Aldrich) mixed with 2 mg of aluminum hydroxide gel (Thermo Fisher Scientific; Waltham, MA, USA) on days 0 and 5. This was followed by daily intranasal administration of 3% OVA diluted in 40 μL of phosphate-buffered saline (PBS) from days 12 to 19. To induce long-term inflammation, mice were exposed to 3% OVA and LPS intranasally three times per week for 12 weeks. Additionally, all NP groups received 500 ng of Staphylococcus aureus enterotoxin B (SEB) (List Biological Laboratories; Campbell, CA, USA) intranasally once a week from days 47 to 102. Mice were randomly divided into five groups as follows: Group A (PBS Control, n = 10), Group B (NP Control, n = 10), Group C (NP + Dnase1 wild-type (WT), n = 10), Group D (NP + Dnase1 AR-CR8, n = 10), Group E (NP + dexamethasone, n = 10). AR-CR8 Dnase1 was administered via intranasal instillation. Specifically, four 5 μL aliquots were applied to each nostril, resulting in a total cumulative volume of 40 μL (equivalent to 4 μg of protein) per mouse. The administration frequency was three times a week. Dexamethasone (20 μg) (Merck) was delivered intraperitoneally once a week for 8 consecutive weeks. To increase viscosity during intranasal administration, Dnase1 formulations were supplemented with 0.1% Hypromellose (Sigma-Aldrich) to prevent Dnase1 from being washed out by mucus. The administration of Dnase1 was conducted from day 47 to 102. Mice were euthanized 24 hours after the last intranasal administration for further analysis. When euthanized, mice were anesthetized with intraperitoneal injection of a mixture (1:1 w/v) of 2,2,2-tribromoethanol and tertiary-amyl alcohol mixture (Avertin, Sigma-Aldrich) at a dose of 1 g/kg. Avertin was chosen because of its effectiveness in inducing deep anesthesia without distress. Animals were monitored for signs of deep anesthesia, such as loss of right turning reflex and unresponsiveness to tail pinch. While anesthetized, mice were sacrificed to collect samples by decapitation. The experimental procedure for inducing CRS and polyps is illustrated in Fig. 1.Fig. 1Schematic diagram of the neutrophilic nasal polyp mouse model Schematic diagram of the neutrophilic nasal polyp mouse model Immunocytochemistry Isolated human neutrophils (2 × 106 per coverslip) were briefly cultured on Poly-L-Lysine-coated glass coverslips (Corning; Darmstadt, Germany). They were stimulated with LPS (100 µg/mL) at 37 °C for 4 hours, and further treated with Dnase1 (WT Dnase1 or AR-CR8 Dnase1) at 37 °C for 1 hour. NETs were then fixed using 4% paraformaldehyde (PFA) (Biosesang; Seongnam, Korea) for 20 minutes. To prevent non-specific binding, the coverslips were blocked with 1% BSA for 1 hour. The coverslips were incubated overnight at 4 °C with anti-citrullinated H3 (Novus; Centennial, CO, USA) (1:400 dilution) and anti-MPO (R&D Systems; Minneapolis, MN, USA) (1:400) antibodies. They were exposed to a donkey anti-goat IgG antibody conjugated with Alexa Fluor Plus 488 (Invitrogen; Carlsbad, CA) and a donkey anti-rabbit IgG antibody conjugated with Alexa Fluor Plus 555 for 45 minutes at room temperature in the dark. Finally, DNAs were visualized using the DAPI (Sigma-Aldrich). Cytotoxicity assay A549 cells (2.0 × 104 cells per well) were plated in 96-well plates and exposed to Dnase1 (12.5 to 200 μg/mL). After incubated for 24 hours, cells were treated with MTT (0.3 mg/mL) and further incubated for 2 hours. The supernatant was then discarded, and the cells were dissolved in DMSO. Absorbance at 570 nm was measured to analyze cell viability. Histology of mouse nasal cavity The mandibles were removed from the heads, and the skins on the heads was excised. The heads were fixed in 4% PFA at 4 °C for 1 day, decalcified in 5% nitric acid (Sigma-Aldrich) at 4 °C for 3 days, and paraffin-embedded. The specimens (4 μm thickness) were cut in coronal section from the second palatal ridge to the first upper molar teeth. The maxillary sinus and ethmoidal labyrinths were identified at the location posterior to two maxillary turbinelles. Hematoxylin and eosin (H&E; Vector Labs, Burlingame, CA) staining was performed to compare microscopic structures between groups, specifically for evaluating nasal polyp-like lesions (NPs). NP was defined as a mucosal bulge with immune cell infiltration and microcavities. The number of NPs were quantified microscopically from 3 coronal sections, and presented as a total number [9]. Immunofluorescence staining For immunofluorescence (IF) staining, the slides of deparaffinized tissues underwent antigen retrieval by microwaving them in 100 mM citrate buffer (pH 6.0) for 10 minutes. To quench endogenous peroxidase activity, the sections were incubated with 3% hydrogen peroxide diluted in methanol for 10 minutes. The slides were then blocked with 5% bovine serum albumin (BSA) in PBS at room temperature for 1 hour. Subsequently, the sections were incubated overnight at 4 °C with anti-citrullinated H3 (Novus) (1:100 dilution) and anti-MPO (R&D) (1:100) antibodies. Then, the slides were incubated with secondary antibodies at RT for 1 hour, and counterstained with DAPI for 10 minutes. The stained slides were analyzed using LSM 800 confocal microscope (Carl Zeiss Microscopy; Göttingen, Germany). The numbers of positively stained cells and NETs were evaluated in four high-power fields (HPFs) and presented as average number. Statistical analysis Statistical analyses were performed using SPSS version 25.0 (IBM Corp.; Armonk, NY, USA). Data are presented as means ± SD. Statistical significance was assessed by Student’s t-test or Kruskal-Wallis test with post-hoc analysis. Asterisk was marked for p < 0.05; n.s. for ‘no significance. Results Molecular design of Dnase1 proteins and their toxicities To enhance the enzymatic activity and tissue penetration of Dnase1 in vivo, we engineered Dnase1 as shown in a previous study [21]. First, the glutamate at position 35 and the alanine at position 136 were substituted with lysine to increase the enzymatic activity. Dnase1 loses its activity by actin binding, and the double mutations can block the interaction between Dnase1 and actin. To enable Dnase1 to penetrate into tissues, the CR8 peptide was conjugated to the protein. The resulting protein was designated as ‘actin-resistant, CR8-fused Dnase1 (AR-CR8 Dnase1)’ (Fig. 2A). As wild-type (WT) and AR-CR8 Dnase1 contain the His (6)-tag, both proteins could be purified using nickel affinity beads (Fig. 2B, Supplementary Fig. S1). To evaluate the cytotoxicities of Dnase1s, A549 lung epithelial cells were treated with increasing concentrations of each Dnase1 protein. The results demonstrated that neither WT Dnase1 nor AR-CR8 Dnase1 were substantially toxic to cells (Fig. 2C).Fig. 2Preparation and cytotoxicity of recombinant proteins of Dnase1. (A) Protein structures of WT Dnase1 and AR-CR8 Dnase1. AR-CR8 Dnase1 carries mutations at positions 35 and 136, and fused with the CR8 domain; (B) His(6)-tagged Dnase1 proteins were purified using nickel-NTA beads. The purified proteins were electrophoresed on SDS-PAGE and stained with by Coomassie Brilliant Blue; (C) To evaluate the cytotoxicity of the purified Dnase1 proteins, A549 cells were treated with up to 200 μg/mL of each protein for 24 hours. Cell viability was analyzed using MTT Preparation and cytotoxicity of recombinant proteins of Dnase1. (A) Protein structures of WT Dnase1 and AR-CR8 Dnase1. AR-CR8 Dnase1 carries mutations at positions 35 and 136, and fused with the CR8 domain; (B) His(6)-tagged Dnase1 proteins were purified using nickel-NTA beads. The purified proteins were electrophoresed on SDS-PAGE and stained with by Coomassie Brilliant Blue; (C) To evaluate the cytotoxicity of the purified Dnase1 proteins, A549 cells were treated with up to 200 μg/mL of each protein for 24 hours. Cell viability was analyzed using MTT WT and AR-CR8 Dnase1 remove NETs effectively in vitro To assess the ability of Dnase1 to degrade NETs, NETosis was induced in human neutrophils using LPS. Recombinant WT Dnase1 and AR-CR8 Dnase1 were applied at a concentration of 200 µg/mL to neutrophils undergoing NETosis. LPS markedly increased the extracellular levels of MPO and citrullinated H3, both of which are representative marks for NETs. WT Dnase1 and AR-CR8 Dnase1were found to reduce the levels of MPO and citrullinated H3 (Fig. 3A), indicating that both enzymes effectively degrade NETs. Such effects were quantitatively analyzed based on citH3-positive and MPO-positive areas (Fig. 3B and C). These results indicated that both Dnase1 proteins eliminated NETs in the culture system. Compared with WT Dnase1, AR-CR8 Dnase1 was shown to remove more effectively NETs in the MPO-DNA co-staining assay, but not significantly in the CitH3 assay. Since the culture system contains just 10% serum, WT Dnase1 may not be substantially inhibited by actin and other proteins in the serum. Therefore, it is not expected that AR-CR8 Dnase1shows a superior activity to WT Dnase1 in the in vitro condition.Fig. 3Effects of Dnase1 proteins on NETs in LPS-stimulated neutrophils. (A) LPS stimulated the formation of NETs in human neutrophils. NETs were visualized by immunofluorescence staining with anti-citrullinated histone H3 (CitH3; red), anti-myeloperoxidase (MPO; green), and DAPI (blue). The stimulated neutrophils were incubated with WT or AR-CR8 Dnase1. Scale bar = 50 μm; (B) Quantification of the area of CitH3-positive signals per field of view. (C) Quantification of MPO and DAPI co-stained area per field of view. Each bar represents the mean ± SD from three independent experiments. Statistical analysis was performed using Student’s t-test (unpaired and two tailed). *, p < 0.05 versus the PBS control; #, p < 0.05 versus the LPS control; †, p < 0.05 versus the WT Dnase1 group Effects of Dnase1 proteins on NETs in LPS-stimulated neutrophils. (A) LPS stimulated the formation of NETs in human neutrophils. NETs were visualized by immunofluorescence staining with anti-citrullinated histone H3 (CitH3; red), anti-myeloperoxidase (MPO; green), and DAPI (blue). The stimulated neutrophils were incubated with WT or AR-CR8 Dnase1. Scale bar = 50 μm; (B) Quantification of the area of CitH3-positive signals per field of view. (C) Quantification of MPO and DAPI co-stained area per field of view. Each bar represents the mean ± SD from three independent experiments. Statistical analysis was performed using Student’s t-test (unpaired and two tailed). *, p < 0.05 versus the PBS control; #, p < 0.05 versus the LPS control; †, p < 0.05 versus the WT Dnase1 group AR-CR8 Dnase1 prevents nasal polyp formation more effectively than WT Dnase1 The nasal cavity sections from CRS mice were stained with H&E, and their gross structures were meticulously observed to evaluate polyp formation. In the present study, the Dnase1 formulations were supplemented with 0.1% hypromellose to prevent the immediate protein removal by mucus. The Dnase1 activities were checked to verify that hypromellose does not significantly affect wild-type and AR-CR8 Dnase1s (Supplementary Fig. S2). Nasal polyps were identified based on three criteria: (1) overgrowing epithelial regions, (2) protruding structures lined by epithelial cells, (3) cellular aggregates infiltrated by immune cells (Fig. 4A). The numbers of polyps were counted and presented as dot blots in Fig. 4B. No polyp was recognized in the nasal cavities of normal mice (Group A), whereas several polyps (mean ± SD) in each nasal cavity specimen were identified in the OVA/LPS-treated group (Group B). Polyp numbers were marginally, not significantly in statistics, reduced by WT Dnase1 administration (Group C). In contrast, polyp numbers were reduced nearly 50% in the AR-CR8 Dnase1 group (Group D) than the OVA/LPS group. Indeed, such an effect of AR-CR8 Dnase1 was similar to that of dexamethasone in reducing polyp number (Group E). Therefore, these results suggest that the nasal administration of AR-CR8 Dnase1 could be a new strategy to reduce the burden of polyps in CRS patients.Fig. 4Effects of Dnase1 and dexamethasone on nasal polyp formation in mice. (A) H&E staining of nasal cavity sections in a mouse nasal polyp model. Areas indicated with squares are shown as magnified images. Scale bar = 1 mm; (B) the number of polyps was counted in each group and presented as dot graphs. Long and short horizontal bars represent the means and SD (N = 10), representatively. Statistical analysis was performed Kruskal-Wallis test with post-hoc analysis. *, p < 0.05; n.s., p > 0.05 Effects of Dnase1 and dexamethasone on nasal polyp formation in mice. (A) H&E staining of nasal cavity sections in a mouse nasal polyp model. Areas indicated with squares are shown as magnified images. Scale bar = 1 mm; (B) the number of polyps was counted in each group and presented as dot graphs. Long and short horizontal bars represent the means and SD (N = 10), representatively. Statistical analysis was performed Kruskal-Wallis test with post-hoc analysis. *, p < 0.05; n.s., p > 0.05 AR-CR8 Dnase1 reduces NET formation in the nasal mucosa of CRS mice To detect NETs in the nasal mucosa, nasal cavity specimens were co-stained for citrullinated H3 (citH3), MPO, and DAPI (Fig. 5A). Based on the NET markers citH3 staining (Fig. 5B) and MPO-DNA co-staining (Fig. 5C), NET-like structures were present in the epithelial layers of the nasal mucosa in Group B, but not in Group A. However, the numbers of NET-like structures were noticeably reduced by administration of WT Dnase1 and AR-CR8 Dnase1 (Groups C and D). As was expected, dexamethasone (Group E) showed a robust effect against NET formation. In quantitative analyses, AR-CR8 Dnase1, versus WT Dnase1, more effectively prevented NET formation in the nasal mucosae of CRS mice. The NET-inhibitory effect of AR-CR8 Dnase1 is as good as that of dexamethasone. These results suggest that the AR-CR8 Dnase1 may reduce polyp burden at least in part by decreasing NET accumulation in the nasal mucosae of CRS mice.Fig. 5Effects of Dnase1 and dexamethasone on NETs in mouse nasal cavities. (A) Representative immunofluorescence images of NETs in mouse nasal mucosa. Samples were stained with anti-CitH3 (red), anti-MPO (green), and DAPI (blue). NETs were evaluated as CitH3 positive or MPO/DAPI double-positive cells. The scale bar represents 20 μm; (B) Numbers of CitH3 positive cells per high-power field; (C) Numbers of MPO/DAPI double-positive cells per high-power field. Long and short horizontal bars represent the means and SD (N = 10), representatively. Statistical analysis was performed Kruskal-Wallis test with post-hoc analysis. * denotes p < 0.05 Effects of Dnase1 and dexamethasone on NETs in mouse nasal cavities. (A) Representative immunofluorescence images of NETs in mouse nasal mucosa. Samples were stained with anti-CitH3 (red), anti-MPO (green), and DAPI (blue). NETs were evaluated as CitH3 positive or MPO/DAPI double-positive cells. The scale bar represents 20 μm; (B) Numbers of CitH3 positive cells per high-power field; (C) Numbers of MPO/DAPI double-positive cells per high-power field. Long and short horizontal bars represent the means and SD (N = 10), representatively. Statistical analysis was performed Kruskal-Wallis test with post-hoc analysis. * denotes p < 0.05 AR-CR8 Dnase1 prevents the destruction of nasal mucosa and the infiltration of immune cells Loss of ciliated cells in the nasal epithelium indicates the impairment of epithelial function, which can be visualized by acetylated tubulin (ac-tubulin) staining (Fig. 6A). The loss of ac-tubulin positive cells in Group B indicated the mucosal destruction with impaired ciliary function and exacerbated inflammation. The nasal administration of Dnase1 proteins preserved the numbers of ac-tubulin positive cells. Particularly, AR-CR8 Dnase1 showed a better effect on the preservation of ciliated cells than WT Dnase1, which is similar to the efficacy of dexamethasone in reducing NET accumulation (Fig. 6B). Given that NETs are known to aggravate inflammation [22, 23], we checked whether Dnase1 suppresses the infiltration of immune cells into the nasal mucosa. T cells and macrophages were identified by immunostaining with anti-CD3 and anti-F4/80 antibodies, respectively (Fig. 6A). Many T cells and macrophages were detected at the nasal mucosa in Group B, but the numbers of immune cells were significantly decreased by Dnase1 administration. AR-CR8 Dnase1, versus WT Dnase1, was more effective in quenching the immune response (Fig. 6C). Collectively, the nasal administration of AR-CR8 Dnase1 may have a beneficial effect on the protection of the nasal mucosa from the immune reaction.Fig. 6Effects of Dnase1 and dexamethasone on mucosal destruction and immune cell infiltration in mouse nasal cavities. (A) Immunofluorescence staining (red) for ciliated cells in the mouse nasal mucosa using anti-acetylated tubulin antibody (1st low panels); T cells using anti-CD3 antibody (2nd low panels); macrophages using anti-F4/80 antibody (3rd low panels). The scale bar represents 20 μm; (B) Numbers of ciliated cells per high-power field; (C) Numbers of T cells and macrophages per high-power field. Long and short horizontal bars represent the means and SD (N = 10), representatively. Statistical analysis was performed using Kruskal-Wallis test with post-hoc analysis. * denotes p < 0.05 Effects of Dnase1 and dexamethasone on mucosal destruction and immune cell infiltration in mouse nasal cavities. (A) Immunofluorescence staining (red) for ciliated cells in the mouse nasal mucosa using anti-acetylated tubulin antibody (1st low panels); T cells using anti-CD3 antibody (2nd low panels); macrophages using anti-F4/80 antibody (3rd low panels). The scale bar represents 20 μm; (B) Numbers of ciliated cells per high-power field; (C) Numbers of T cells and macrophages per high-power field. Long and short horizontal bars represent the means and SD (N = 10), representatively. Statistical analysis was performed using Kruskal-Wallis test with post-hoc analysis. * denotes p < 0.05 Discussion NETs in neutrophilic CRS have been reported to be involved in epithelial damage and persistent inflammation [24]. Recently, deoxyribonuclease 1 has been evaluated as a therapeutic agent to eliminate the DNA-based NETs in various inflammatory diseases [9, 25]. This study aimed to validate a therapeutic potential of a genetically engineered Dnase1 for nasal polyps. Polyps were induced in nasal epithelial cells using LPS in a neutrophilic CRS mouse model. We engineered AR-CR8 Dnase1 with enhanced stability and tissue permeability to remove NETs in the nasal cavity. We demonstrated the inhibitory effects of the Dnase1 on NET accumulation, immune cell infiltration, and nasal polyp formation in mouse nasal cavities. Given Previous studies suggesting that polyps develop during SEB treatment [26], we assumed that AR-CR8 Dnase1 was administered at the onset of polyp while SEB was administered. We investigated the potential of Dnase1 as a therapeutic agent rather than a preventive medicine. It is very hard to remove pre-existing polyps. Nonetheless, we need to develop new drugs as therapeutics to reduce sinusitis symptoms and the burden of polyps. In the present study, we propose that AR-CR8 Dnase1could be a potential material used in emerging biopharmaceutics to ameliorate inflammation and reduce the burden of nasal polyps. The intranasal administration of a protein-based agent is highly limited due to its poor absorption through the mucosal barrier. However, AR-CR8 Dnase1 harboring 8 arginine residues exhibited relatively higher absorption compared to WT Dnase1 [21]. As previously demonstrated, AR-CR8 Dnase1 was originally designed for its penetration into cells. However, AR-CR8 Dnase1 was shown to be absorbed systemically through the rectal mucosa. The absorbed AR-CR8 Dnase1 could remove NETs in the blood of mice subjected to sepsis. Consequently, AR-CR8 Dnase1 might have a potential for tissue penetration beyond cell penetration, which prompted us to try the intranasal administration of AR-CR8 Dnase1. In this study, we demonstrated that the intranasal administration of AR-CR8 Dnase1 reduced the numbers of NETs in the nasal cavities of CRS mice. How does AR-CR8 Dnase1 target NETS inside of mucosal and submucosal layers? It is reasonable that the CR8 motif helps Dnase1 enter into the epithelial cell barrier, because the cell-penetrating effect of CR8 has been confirmed elsewhere [21]. However, AR-CR8 Dnase1 should pass through two liquid layers, the mucus layer and the periciliary layer, before reaching the epithelial cell layer. The liquid layers function to trap inhaled particles like dust, allergens, and microbes. Likewise, the layers are expected to trap instilled AR-CR8 Dnase1 as well. Considering that AR-CR8 Dnase1 is soluble in water, AR-CR8 Dnase1 may be dissolved in the liquid layers. If so, the liquid layers may act as a reservoir to contain AR-CR8 for a while. The liquid layers could obstruct the mucosal delivery of AR-CR8 Dnase1 or help AR-CR8 Dnase1 stick around the mucosa. Indeed, any experiment about the local delivery of AR-CR8 Dnase1 was not done in the present study. The efficacy of AR-CR8 Dnase1 on local delivery remains to be checked. In this study, we investigated the pathophysiology of neutrophilic chronic rhinosinusitis (CRS) using a murine model induced by intranasal administration of Staphylococcus aureus enterotoxin B (SEB) and LPS. This model successfully recapitulated key histopathological features of human neutrophilic CRSwNP, including distinct neutrophilic infiltration, submucosal hypertrophy, and polypoid lesion formation. Despite these similarities, several limitations must be acknowledged. First, fundamental anatomical differences between murine and human sinonasal structures make it difficult to fully reproduce the massive or multiple polypoid structures in mice. Second, as the model relies heavily on exogenous bacterial provocation, it may not capture the complex, multifactorial etiology of human CRSwNP, which involves viruses, allergens, epithelial barrier dysfunction, and mechanical stress. Third, the temporal dynamics of the immune response differ significantly; while human CRS evolves over years, this experimental model induces pathology acutely. This discrepancy may limit the model’s ability to replicate subtle, long-term processes such as chronic immune regulation, extensive tissue remodeling, and fibrosis. Finally, the translational predictive power regarding therapeutic response remains uncertain. For instance, while the IL-17A axis and related pathways (e.g., mTOR) are emerging targets in human neutrophil-driven CRS [27], further validation is required to determine if this model accurately predicts clinical efficacy for biologics or immunomodulators. Nevertheless, this model remains a valuable tool for elucidating the pathogenesis of neutrophilic CRS, characterizing inflammatory mediators, dissecting cellular signaling pathways, and conducting preclinical evaluations of novel therapeutics. Developing a nasal spray for Dnase1 requires a delicate balance between formulation stability, viscosity, and the maintenance of biological activity. To achieve this, polymers like low-concentration HPMC are standardly utilized to provide mucoadhesion; this ensures adequate retention on the nasal mucosa and consistent local drug exposure while maintaining the fluid dynamics necessary for effective spray. Clinically, this approach capitalizes on the benefits of intranasal delivery, specifically the direct and rapid access to the upper airway. Overall, the data suggest that a stabilized aqueous formulation with viscosity-enhancing excipients is a feasible strategy for human application, provided that critical quality attributes, such as protein stability, spray performance, and local safety, are verified. In general, the clinical application of protein-based drugs like AR-CR8 Dnase1 is limited in terms of their physicochemical properties and host responses to artificial proteins. For instance, proteins drugs inevitably make immunogenic issues. The generation of anti-drug antibodies can lead to decreased efficacy due to neutralizing drugs or make hypersensitivity reactions by immune complexes [28]. Therefore, monitoring of drug activity and anti-drug antibody formation is recommended for patients subjected to a long-term administration of a protein drug. Particularly, to develop the intranasal formula (spray or drop) of protein drugs, some chemical stabilizers should be used to preserve the physicochemical property and the biological activity of the proteins. In some cases, the preservatives may cause side effects [29]. In addition, even after the DNA backbone of NETs is degraded by deoxyribonuclease 1, protein components such as histones and proteases (elastase, MPO, etc.) can remain in the tissues, causing tissue damage and inflammation. Also, since NETs capture pathogens in an infectious situation, deoxyribonuclease 1 administration can weaken the NET-driven defense system against infection. Therefore, the clinical use of nasal deoxyribonuclease 1 drugs should be carefully considered in case of CRS accompanied by infection. Given that dexamethasone is currently the standard of care for CRS, we compared the therapeutic efficacy of AR-CR8 Dnase1 against this synthetic corticosteroid in our animal model. Consequently, AR-CR8 Dnase1 demonstrated efficacy comparable to that of dexamethasone, suggesting its potential as a steroid-sparing alternative. However, a direct comparison of therapeutic effect is constrained by the disparity in administration routes; while AR-CR8 Dnase1 was delivered intranasally, dexamethasone was administered systemically. Such differences in delivery routes can significantly alter pharmacokinetics and local bioavailability. Furthermore, the observation that AR-CR8 Dnase1 matches dexamethasone’s efficacy does not simply imply utility in steroid-resistant patients. The multifactorial mechanisms driving steroid resistance—including anatomical obstruction, mucosal microenvironmental changes, and specific cytokine profiles—could similarly impede the efficacy of Dnase1. Therefore, determining whether AR-CR8 Dnase1 can serve as a substitute for corticosteroids, remains an open question and represents a notable limitation of this study. The key finding in this study is that AR-CR8 Dnase1 was validated as a biopharmaceutic agent applicable for treating neutrophilic CRS. More importantly, the therapeutic effect of AR-CR8 Dnase1 was similar to that of dexasamethasone injection in our animal model. In clinical practice, a long-term usage of steroids is not recommended because of many local and systemic side effects. A long-term use of topical steroids often causes epistaxis, nasal dryness/irritation, throat irritation, and headache [30], and occasionally make more serious complications, including nasal mucosal atrophy, ulceration, or perforation [31, 32]. Moreover, some patients do not respond to steroid therapy. Therefore, if AR-CR8 Dnase1 will be developed as a bio-drug, it could be alternatively used for the CRS patients unsuitable for steroid therapy. Further studies comparing dosing, durability, and safety are needed before considering steroid-sparing clinical use. Conclusions Our findings suggest that AR-CR8 Dnase1 mitigates inflammation and polyp generation in CRS by decomposing NETs. This study highlights the genetically engineered Dnase1 as a potential material to develop an adjunctive agent for neutrophilic CRS, particularly in patients with limited response to corticosteroids. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1